# Synlogic, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Synlogic, Inc.). ## Overview Synlogic, Inc. is a U.S.-based biopharmaceutical company organized around engineered bacterial therapeutics and related research programs. The company was originally built to develop treatments for rare metabolic disorders and operates through Synlogic, Inc. and its subsidiaries from the United States. ## Products & services • Engineered bacterial therapeutics for rare metabolic disorders • Labafenogene marselecobac (SYNB1934) • SYNB1353 for homocystinuria (HCU) • Strategic collaboration, licensing and consulting arrangements - **Clinical-stage therapeutic programs** (0%) — Drug candidates and platform programs aimed at treating rare metabolic diseases. - **Collaborative research and consulting** (100%) — Non-product arrangements such as material transfer and consulting work. - Engineered bacterial therapeutics for rare metabolic disorders - Labafenogene marselecobac (SYNB1934) - SYNB1353 for homocystinuria (HCU) - Strategic collaboration, licensing and consulting arrangements ## Customers Synlogic's direct customers have historically been collaboration partners, research counterparties, and other strategic transaction counterparties rather than commercial patients or hospitals. Its therapeutic programs are aimed at patients with rare metabolic disorders such as phenylketonuria and homocystinuria, but the company has not operated a commercial product business. - **Strategic transaction counterparties** (primary) — Companies or investors evaluating a merger, sale, or other strategic transaction. - **Pharmaceutical collaboration partners** (secondary) — Partners that may license, fund, or co-develop therapeutic assets or platform capabilities. - **Research and consulting clients** (secondary) — Counterparties purchasing limited scientific or consulting services under non-product agreements. - **Rare disease patients and physicians** (emerging) — The intended end users of the company's metabolic disorder programs, especially PKU and HCU. - Pharmaceutical collaboration partners seeking platform or asset access - Research counterparties under material transfer or consulting agreements - Potential merger or acquisition counterparties in strategic review - Patients with rare metabolic disorders as the ultimate end market ## Geography Synlogic is headquartered in the United States and its corporate, research, and administrative activities have been centered there. Its disclosed development work has included global clinical study activity, but the company does not report a broad commercial manufacturing or sales footprint. - United States is the core operating base and corporate headquarters - Clinical development has included global study activity - No disclosed commercial manufacturing network - Geography matters mainly through trial execution and partner access ## Strategy The company's stated strategy is centered on pursuing strategic alternatives to enhance stockholder value, including a merger, sale, or other transaction. Operationally, it has substantially reduced its internal footprint and relies on a very small team and consultants while it evaluates transaction opportunities. - **Complete a strategic transaction** (short-term) — The company is focused on maximizing value through a merger, sale, or similar deal. - **Preserve cash and operating flexibility** (short-term) — A lean structure helps extend runway while alternatives are evaluated. - **Protect intellectual property and asset value** (medium-term) — Any transaction value depends on the remaining technology, patents, and know-how. - Pursue strategic alternatives such as a merger or sale - Preserve optionality while evaluating transaction counterparties - Maintain minimal operations and outsourced support - Protect remaining intellectual property and corporate value ## Risks Synlogic faces high execution risk because it is a non-operating shell company with no commercial product revenue and a very limited operating base. Its securities have been delisted from Nasdaq, and the outcome of any strategic transaction is uncertain, which can materially affect liquidity, valuation, and shareholder outcomes. - **Nasdaq delisting and OTC trading** [high] — Reduced exchange access can lower liquidity, coverage, and financing flexibility. - **Non-operating shell company status** [high] — The company has substantially wound down operations, limiting standalone business prospects. - **Strategic transaction uncertainty** [high] — A merger or sale may not be completed or may not deliver expected value. - **Biopharmaceutical development failure** [medium] — Clinical and regulatory outcomes are inherently uncertain and capital intensive. - **Key-person and operating concentration** [medium] — A very small team makes the company dependent on a few individuals and advisors. - No commercial product revenue and no approved product business - Delisting reduces liquidity and market access for the stock - Strategic transaction may not occur or may not create value - Very small workforce increases key-person and execution risk - Biopharma development remains capital-intensive and uncertain ## Accounting Synlogic's accounting is dominated by judgmental estimates around warrants, restructuring-related charges, and the valuation of remaining assets and obligations. Revenue recognition has become less central because the company no longer expects product revenue, so investors should focus on how non-cash fair value changes and one-time charges affect reported results. - **Purchase warrant liability fair value** — Affects other income/expense and net loss - **Restructuring and other charges** — Affects operating expenses and reported loss - **Revenue recognition** — Affects comparability of legacy collaboration periods - **R&D expense estimation** — Affects operating expense trend analysis - Fair value of purchase warrant liability can swing reported earnings - Restructuring and other charges reflect wind-down and reorganization costs - Revenue recognition is no longer a critical policy in the current model - R&D expense estimates matter less as operations have been reduced - Cash runway and going-concern style disclosures remain important --- *Last updated: 2026-04-29T04:57:12.035483+00:00*